197 related articles for article (PubMed ID: 7642260)
1. The C-terminal domain is essential for protective activity of the Bordetella pertussis adenylate cyclase-hemolysin.
Betsou F; Sebo P; Guiso N
Infect Immun; 1995 Sep; 63(9):3309-15. PubMed ID: 7642260
[TBL] [Abstract][Full Text] [Related]
2. Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin.
Lee SJ; Gray MC; Guo L; Sebo P; Hewlett EL
Infect Immun; 1999 May; 67(5):2090-5. PubMed ID: 10225859
[TBL] [Abstract][Full Text] [Related]
3. CyaC-mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin.
Betsou F; Sebo P; Guiso N
Infect Immun; 1993 Sep; 61(9):3583-9. PubMed ID: 8359880
[TBL] [Abstract][Full Text] [Related]
4. Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization.
Guiso N; Szatanik M; Rocancourt M
Microb Pathog; 1991 Dec; 11(6):423-31. PubMed ID: 1795632
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to Bordetella pertussis adenylate cyclase toxin in neonatal and maternal sera.
Arciniega JL; Hewlett EL; Edwards KM; Burns DL
FEMS Immunol Med Microbiol; 1993 Apr; 6(4):325-30. PubMed ID: 8499896
[TBL] [Abstract][Full Text] [Related]
6. Virulence of Bordetella bronchiseptica: role of adenylate cyclase-hemolysin.
Gueirard P; Guiso N
Infect Immun; 1993 Oct; 61(10):4072-8. PubMed ID: 8406794
[TBL] [Abstract][Full Text] [Related]
7. The Bordetella adenylate cyclase repeat-in-toxin (RTX) domain is immunodominant and elicits neutralizing antibodies.
Wang X; Gray MC; Hewlett EL; Maynard JA
J Biol Chem; 2015 Feb; 290(6):3576-91. PubMed ID: 25505186
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.
Boehm DT; Hall JM; Wong TY; DiVenere AM; Sen-Kilic E; Bevere JR; Bradford SD; Blackwood CB; Elkins CM; DeRoos KA; Gray MC; Cooper CG; Varney ME; Maynard JA; Hewlett EL; Barbier M; Damron FH
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30012638
[No Abstract] [Full Text] [Related]
9. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species.
Khelef N; Danve B; Quentin-Millet MJ; Guiso N
Infect Immun; 1993 Feb; 61(2):486-90. PubMed ID: 8423077
[TBL] [Abstract][Full Text] [Related]
10. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.
Grimprel E; Bégué P; Anjak I; Njamkepo E; François P; Guiso N
Clin Diagn Lab Immunol; 1996 Jan; 3(1):93-7. PubMed ID: 8770511
[TBL] [Abstract][Full Text] [Related]
11. Cyclic AMP-Elevating Capacity of Adenylate Cyclase Toxin-Hemolysin Is Sufficient for Lung Infection but Not for Full Virulence of Bordetella pertussis.
Skopova K; Tomalova B; Kanchev I; Rossmann P; Svedova M; Adkins I; Bibova I; Tomala J; Masin J; Guiso N; Osicka R; Sedlacek R; Kovar M; Sebo P
Infect Immun; 2017 Jun; 85(6):. PubMed ID: 28396322
[TBL] [Abstract][Full Text] [Related]
12. Delivery of CD8(+) T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites.
Osicka R; Osicková A; Basar T; Guermonprez P; Rojas M; Leclerc C; Sebo P
Infect Immun; 2000 Jan; 68(1):247-56. PubMed ID: 10603395
[TBL] [Abstract][Full Text] [Related]
13. Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection.
Khelef N; Sakamoto H; Guiso N
Microb Pathog; 1992 Mar; 12(3):227-35. PubMed ID: 1614333
[TBL] [Abstract][Full Text] [Related]
14. Identification by in vitro complementation of regions required for cell-invasive activity of Bordetella pertussis adenylate cyclase toxin.
Iwaki M; Ullmann A; Sebo P
Mol Microbiol; 1995 Sep; 17(6):1015-24. PubMed ID: 8594322
[TBL] [Abstract][Full Text] [Related]
15. Structure-function studies of the adenylate cyclase toxin of Bordetella pertussis and the leukotoxin of Pasteurella haemolytica by heterologous C protein activation and construction of hybrid proteins.
Westrop G; Hormozi K; da Costa N; Parton R; Coote J
J Bacteriol; 1997 Feb; 179(3):871-9. PubMed ID: 9006045
[TBL] [Abstract][Full Text] [Related]
16. Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen.
Guiso N; Rocancourt M; Szatanik M; Alonso JM
Microb Pathog; 1989 Nov; 7(5):373-80. PubMed ID: 2622329
[TBL] [Abstract][Full Text] [Related]
17. Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin.
Khelef N; Guiso N
FEMS Microbiol Lett; 1995 Dec; 134(1):27-32. PubMed ID: 8593951
[TBL] [Abstract][Full Text] [Related]
18. Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyaA toxin of Bordetella pertussis abolish virulence.
Gross MK; Au DC; Smith AL; Storm DR
Proc Natl Acad Sci U S A; 1992 Jun; 89(11):4898-902. PubMed ID: 1594590
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils.
Weingart CL; Mobberley-Schuman PS; Hewlett EL; Gray MC; Weiss AA
Infect Immun; 2000 Dec; 68(12):7152-5. PubMed ID: 11083845
[TBL] [Abstract][Full Text] [Related]
20. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus.
Saron MF; Fayolle C; Sebo P; Ladant D; Ullmann A; Leclerc C
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3314-9. PubMed ID: 9096390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
